

Endothelial stem cells attenuate cardiac apoptosis via downregulating cardiac microRNA-146a in a rat model of coronary heart disease

YEQING FANG¹, SHAOYUAN CHEN¹, ZHENGUO LIU², WEN AI¹, XIAOFANG HE³,
LEI WANG¹, PEIYI XIE¹, BIMEI JIANG^{2,4} and HONGCHENG FANG⁵

¹Department of Cardiology, Shenzhen Nanshan People's Hospital, Shenzhen, Guangdong 518000, P.R. China;

²Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 51027, USA; ³Department of Oncology and Hematology, The Eighth Affiliated Hospital, Sun Yat-Sen University,

Zhongshan, Guangdong 518033; ⁴Department of Burns and Plastic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008; ⁵Department of Cardiology, Shenzhen Shajin Hospital, Shenzhen, Guangdong 518000, P.R. China

Received January 24, 2018; Accepted August 24, 2018

DOI: 10.3892/etm.2018.6702

Abstract. Coronary artery disease (CAD) is one of the main causes of hospitalization worldwide and has high morbidity. It has previously been demonstrated that stem cells serve an important role in improving myocardial function. MicroRNA (miRNA)-146a downregulation has been reported to inhibit vascular smooth muscle cell apoptosis in a rat model of coronary heart disease. The aim of the present study was to investigate the mechanisms underlying the effects of endothelial stem cell (ESC)-derived paracrine factors and cardiac miRNAs in CAD. Acute myocardial infarction was induced in 20 rats. Autologous ESCs (n=10; experimental group) or PBS (n=10; control group) were injected in the border zone. Reverse transcription-quantitative polymerase chain reaction, ELISA and immunohistochemistry assays were performed to analyze the therapeutic effects of ESCs in rats with coronary heart disease rats. Serum interleukin (IL)-1, IL-17 and tumor necrosis factor- α were reduced in the experimental group compared with control rats, as was the number of circulating proatherogenic cells. The results demonstrated that ESC transplantation markedly down-regulated miRNA-146a expression and decreased apoptosis in the myocardium compared with the control group. Rats in the experimental group also had higher levels of vascular endothelial growth factor compared with the control group. In addition, it was demonstrated that miRNA-146 knockdown reduced cardiac apoptosis and increased VEGF expression. Furthermore, the infarct area in the border zone or rats with CAD was reduced

in the experimental group compared with the control group. In conclusion, these results suggest that ESC transplantation may improve cardiac function via downregulating miR-146a, which may have potential as a treatment for CAD.

Introduction

Coronary artery disease (CAD) is typically caused by the development of atherosclerotic lesions and results in myocardial ischemia (1,2). CAD is associated with inflammation and thrombosis, which can cause luminal stenosis or occlusion (3). Prospective trials have indicated that the morbidity and mortality of myocardial infarction is increasing worldwide since 1990 (2,4). A review of the available clinical data has suggested that cardiovascular interventions, including stent implantation and radiofrequency ablation may help to reduce the mortality of myocardial infarction (5). A large number of proteins have been reported to protect the host against myocardial ischemia and reperfusion injury by modulating myocardial apoptosis and inflammation (6,7). Research has demonstrated that early apoptotic myocardial vascular disease may increase the incidence rate of myocardial infarction (8,9).

The potential use of stem cell transplantation to treat human diseases has been widely investigated (10-12). Currently, stem cell transplantation is a therapeutic protocol used to treat CAD, as stem cells are able to migrate to damaged cardiac tissue, repair the myocardial infarction area and ultimately reduce infarct-associated mortality (13). A previous study reported that bone marrow stem cell mobilization is able to decrease left ventricular ejection fraction, stroke volume and cardiac output for patients with coronary heart disease (14). Ghem *et al* (15) demonstrated that endothelial stem/progenitor cells (EPCs), mesenchymal stem/progenitor cells (MSCs), and hematopoietic stem/progenitor cells (HSCs) decreased left ventricular dysfunction, diabetes and intermediate risk in patients with cardiovascular diseases. However, the role and potential mechanism of endothelial stem cells (ESCs) in cardiac cells is not well understood.

Correspondence to: Professor Hongcheng Fang, Department of Cardiology, Shenzhen Shajin Hospital, 3 Xinsha Road, Shenzhen, Guangdong 518000, P.R. China
E-mail: fangyanchengedu@163.com

Key words: endothelial stem cells, microRNA-146a, coronary heart disease, vascular endothelial growth factor, apoptosis

In the present study, the therapeutic effects of ESCs in a rat model of CAD were assessed, as well as the underlying mechanism. The effects of ESCs on serum cytokine levels and circulating proatherogenic cells were also investigated.

Materials and methods

Animal study. The present study was approved by the Ethics Committee of Shenzhen Nanshan People's Hospital (Shenzhen, China). A total of 20 female Sprague-Dawley rats (6–8 weeks of age, body weight: 200–220 g) were purchased from the Chinese Academy of Sciences (Shanghai, China). All rats were housed at 23°C with 50% humidity and a 12 h light/dark cycle. Rats were provided with free access to food and water. Rats were injected with vitamin D3 once every 30 days (2×10^6 U/kg) and received a high-fat diet containing 2% cholesterol, 3% lard oil, 0.5% sodium cholate, 0.2% propylthiouracil and 94.3% basic diet supplemented with vitamin D3 (1.25×10^6 U/kg) to establish acute myocardial infarction. Rats were then divided into the experimental ($n=10$) and negative control groups ($n=10$). Rats were anesthetized with 35 mg/kg pentobarbital intravenously, following which they received an intra-myocardial injection of 1×10^4 ESCs (Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran) in 100 μ l PBS (experimental group) or an equal volume of PBS (control group). At 10 days after treatment, rats were sacrificed and heart tissues were harvested. Tissues were either snap-frozen in liquid nitrogen or fixed in 10% formalin solution (Ph 7.4) for 15 min at 37°C for further analysis. The total experimental period was 42 days.

Cardiac function analysis. Rats were fed with the aforementioned diet for 30 days, injected with PBS or ESCs, left for 10 days and then sacrificed. Rats were fed with the specified diet for 30 days. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured using Blood Pressure Monitors (BP786N; Omron, Kyoto, Japan) for experimental rats between ESCs and control groups on day 42. Heart rate of experimental rats was measured using a heart rate detector (Prince 180D; Heal Force Bio-meditech Holdings, Ltd., Shanghai, China).

ELISA. Central venous blood samples (5 ml) were collected from rats in each group on day 42. Following centrifugation at $3,000 \times g$ for 15 min at 4°C, serum levels of aspartate transaminase (AST; E-EL-M0160), lactate dehydrogenase (LDH; cat. no. TWp001252; Shanghai Jianglai Biological Technology Co., Ltd., Shanghai, China), Troponin T (TnT; cat. no. 0-113685, JiangLai Biology, Shanghai Jianglai Biological Technology Co., Ltd.), TnI (cat. no. YBE-0070Q; Shanghai Jianglai Biological Technology Co., Ltd.) interleukin (IL)-1 β (RLB00; R&D Systems, Inc., Minneapolis, MN, USA), IL-17a (M1700; R&D Systems, Inc.) and tumor necrosis factor (TNF)- α (RTA00; R&D Systems, Inc.) were measured using commercial ELISA kits according to the manufacturer's protocol. The results were read using an ELISA microplate reader at 450 nm (Spectra Max 190, Molecular Devices LLC, Sunnyvale, CA, USA).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from heart tissues (1.0 g) using an RNAeasy Mini kit (Qiagen AB, Sollentuna,

Sweden). The concentration of RNA samples were measured using a Nanodrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Total RNA (1 μ g) was reverse-transcribed to cDNA using a Transcriptor First Strand cDNA Synthesis kit (Invitrogen; Thermo Fisher Scientific, Inc.). Micro (mi)RNA expression was assessed using an miRNA microarray analysis with the miRCURY LNA™ miRNA Array (Qiagen AB) according to the manufacturer's protocol. All miRNA primers were synthesized by Invitrogen (Thermo Fisher Scientific, Inc.). Primers used were as follows: miRNA-146a forward, AUGCCAUUGCGAGGGAUUUCG-3'; and reverse, 5'-ATACCTTCAGAGCCTGAGACTCTGCC-3'; RNU6B (U6) forward, 5'-CGCAAGGAUGACACGCAAAUUCGUGAAGCGUCCAUUUUUU-3' and reverse, 5'-GATATCCCAGCTGAAGAACTGAATTTGAC-3'. RT-qPCR reaction was performed using a TaqMan™ MicroRNA Reverse Transcription kit (cat. no. 4366596; Invitrogen; Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: 2 min at 95°C; followed by 40 cycles of 10 sec at 95°C, annealing for 20 sec at 55°C and a primer extension for 30 sec at 72°C and then for 10 min at 72°C. The microarray data was validated using real-time PCR with TaqMan probes and relative miRNA expression levels were normalized using the RNU6B (U6) small non-coding RNA as control. Expression was calculated using the $2^{-\Delta\Delta C_q}$ method (16).

MiRNA-146a overexpression. Myocardial cells (1×10^5 cells/well) from experimental rats were cultured in 6-well plates until they reached 90% confluence, following which the medium was discarded. Cells were subsequently transfected with 10 pmol plentivirus-miRNA-146a (pmiRNA-146a, 5'-UACGCCCUUUUACAUGCAUCG-3') or 10 pmol miRNA-146a-mimic control (pControl, 5'-ACGUACUUUUGUGUAGUACC-3') using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) in Opti-MEM medium according to the manufacturer's protocol. Cells were used for further analysis following 72 h transfection.

Knockdown of miRNA-146a. Myocardial cells (1×10^5 cells/well) were seeded in 6-well plates for 12 h at 37°C. Cells were washed with PBS three times. Small interfering (si)RNR-miRNA-146a (miRNA-146aKN) and siRNR-mimic (Control) were synthesized by Guangzhou RiboBio Co., Ltd. (Guangzhou, China). Sequences were as follows: miRNA-146aKN, 5'-CCUGCUGGAUUGAGCUACACCUGAA-3' and siRNR-mimic, 5'-CUCGUCUCAUUGATGACAGTT-3'. SiRNAs (100 pmol) were transfected into myocardial cells using RNAi MAX (Thermo Fisher Scientific, Inc.) according to the manufacturers' protocol. Further experiments were performed at 72 following transfection.

Viability of myocardial cells. Myocardial cells (2×10^3 cells/well) were seeded in 96-well plates and cultured at 37°C for 12 h. A CCK-8 detection kit (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was used to measure cell viability according to the manufacturer's protocol.

Western blotting. Myocardial tissues (5 μ g) were homogenized in lysate buffer containing protease-inhibitor (Sigma-Aldrich;

Merck KGaA) and centrifuged at 8,000 x g for 10 min at 4°C. The protein concentration was measured using a BCA protein assay kit (Thermo Fisher Scientific, Inc.). Protein samples (20 µg) were separated by 15% SDS-PAGE and transferred onto a polyvinylidene fluoride membrane. After blocking for 1 h at 37°C with 10% Bovine Serum Albumin (cat. no. 10735108001; Roche Applied Science, Penzburg, Germany), the membrane was incubated with primary antibodies against the following: Vascular endothelial growth factor (VEGF; 1:1,000; ab32152; Abcam, Cambridge, UK), IL-6 (1:1,000; ab9324; Abcam), intercellular adhesion molecule 1 (ICAM-1; 1:1,000; sc-7891, Santa Cruz Biotechnology, Inc., Dallas, TX, USA), FAS (1:1,000; ab82419; Abcam), TNF-α (1:1,000; ab6671, Abcam) and β-actin (1:2,000; cat. no. ab8226; Abcam) for 12 h at 4°C. The membrane was next incubated with horseradish peroxidase-conjugated anti-rabbit IgG antibody (1:2,000; PV-6001, OriGene Technologies, Inc., Rockville, MD, USA) for 24 h at 4°C. The results were visualized by using a chemiluminescence kit (Pierce; Thermo Fisher Scientific, Inc.).

Immunological staining. Immunohistochemistry was performed as previously described (17). Cardiac tissues were prepared, fixed in 4% paraformaldehyde for 2 h at 37°C, embedded in paraffin and cut into 4 µm sections. Epitope retrieval was performed using Tris-HCl buffer (AP-9005-050; Thermo Fisher Scientific, Inc.). The paraffin sections were quenched with hydrogen peroxide (3%) for 15 min at 37°C, and subsequently blocked with 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA) for 15 min at 37°C. Cardiac tissue sections were rinsed with PBS and incubated with rabbit anti-rat primary antibodies against VEGF (1:1,000), sFAS (1:1,000) and TNF-α (1:1,000) for 12 h at 4°C. Sections were washed with PBS for 30 min at room temperature and incubated with Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488; 1:2,000; ab150077; Abcam) for 2 h at 37°C. The results were visualized by using an enhanced chemiluminescence kit (Pierce; Thermo Fisher Scientific, Inc.). Densitometry was performed using Quantity-One software 1.2 (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

TUNEL analysis. A TUNEL assay was performed to assess the apoptosis of myocardial cells in rats. Cardiac tissue sections were stained using TUNEL with an *In Situ* Cell Death Detection kit (Roche Applied Science) according to the manufacturer's protocol. Images of tissue sections were captured using a ZEISS LSM 510 confocal microscope at 488 nm (ZEISS AB, Oberkochen, Germany). Images were analyzed using ImageJ software 2.0 (National Institutes of Health, Bethesda, MA, USA).

Statistical analysis. All data are expressed as the mean ± standard deviation of three independent experiments. Data were compared using Student's t test with SPSS version 19. (IBM, Corp., Armonk, NY, USA) and P<0.05 was considered to indicate a statistically significant difference.

Results

ESCs therapy improves cardiac function in a rat model of CAD. The therapeutic effects of ESCs on cardiac function

Table I. Plasma total cholesterol, HDL-cholesterol, LDL-cholesterol and triacylglycerides indices.

Plasma component	Concentration (mg/dl)		
	Baseline	Control group	ESCs group
Total cholesterol	172.25±8.82	163.58±7.54	81.10±5.42 ^{a,b}
HDL-cholesterol	64.66±6.28	62.46±5.12	41.36±3.06 ^{a,b}
LDL-cholesterol	110.24±7.20	112.85±6.85	70.54±6.40 ^{a,b}
Triacylglycerides	42.15±4.32	43.25±5.24	30.22±3.06 ^{a,b}

Values are expressed as the mean ± standard deviation. ^aP<0.01 vs. baseline and ^bP<0.01 vs. control group. ESCs, endothelial stem cells; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

were investigated in a rat model of CAD. The results revealed that ESCs therapy decreased SBP and DBP in CAD rats compared with the control group (Fig. 1A). ESCs therapy also decreased serum AST, LDH (Fig. 1B), TnT and TnI (Fig. 1C) compared with the control group. The results also demonstrated that ESCs therapy improved rats' heart rate compared with the control group (Fig. 1D). ESCs therapy improved the atherosclerosis indices compared with the control group (Table I). These data suggest that ESCs therapy is able to improve cardiac function in a rat model of CAD.

ESCs therapy decreases serum cytokine levels and circulating proatherogenic cells in a rat model of CAD. The anti-inflammatory effects of ESCs were investigated in a rat model of CAD. The results demonstrated that ESCs treatment decreased IL-1, IL-17 and TNFα serum levels compared with the control group (Fig. 2A). Rats treated with ESCs had fewer progenitor cells, including stem cells antigen-1-negative progenitors (SCA1P), common myeloid progenitors (CMP), granulocyte-macrophage progenitors (GMP) and megakaryocyte-erythroid progenitors (MEP) (Fig. 2B). These results suggest that ESCs therapy could decrease serum cytokine levels and circulating proatherogenic cells in rats with CAD.

ESCs therapy decreases myocardial infarction in a rat model of CAD. Myocardial infarctions and cardiac apoptosis were analyzed on day 30 after ESCs therapy. Rats treated with ESCs therapy exhibited smaller infarct areas in the border zone compared with control rats (Fig. 3A). The results demonstrated that ESCs therapy increased VEGF expression compared with the control group (Fig. 3B). Markers of myocardial apoptosis, sFas and TNFα, were decreased by ESCs therapy compared with the control group (Fig. 3C). These results suggest that ESCs therapy may decrease myocardial infarction size in a rat model of CAD.

ESCs therapy regulates cardiac apoptosis via downregulating miRNA-146a. As presented in Fig. 4A, miRNA-146a expression was decreased in myocardial cells isolated from rats treated with ESCs compared to those from the control




Figure 1. ESCs therapy improves cardiac function in a rat model of coronary heart disease. (A) Effects of ESCs therapy on (A) SBP and DBP, (B) serum AST and LDH, (C) serum TnT and TnI and (D) heart rate in a rat model of CAD. **P<0.01. ESCs, endothelial stem cells; SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate transferase; LDH, lactic dehydrogenase; Tn, Troponin.




Figure 2. ESCs therapy decreases serum cytokine levels and circulating proatherogenic cells in a rat model of coronary heart disease. (A) Serum IL-1, IL-17 and TNF-α levels and (B) stem cells antigen-1 negative progenitors, common myeloid progenitors, granulocyte-macrophage progenitors and megakaryocyte-erythroid progenitors were decreased in rats treated with ESCs compared with the control group. **P<0.01. ESCs, endothelial stem cells; IL, interleukin; TNF, tumor necrosis factor.

group. Transfection with miRNA-146aKN decreased VEGF, IL-6 and sICAM-1 protein expression in myocardial cells compared with cells transfected with miRNA-mimic (Fig. 4B). Transfection with pmiRNA-146a the decreased viability of myocardial compared with cells transfected with miRNA-mimic (Fig. 4C). sFas and TNFα expression was also downregulated by miRNA-146a knockdown compared with the miRNA-mimic group (Fig. 4D). These results suggest that ESCs therapy regulates cardiac apoptosis by downregulating miRNA-146a expression.

Discussion

CAD is associated with an increase in the expression of inflammatory cytokines (18). It has previously been reported that miR-146a serves an essential role in inflammatory signaling pathways and the formation of

atherosclerotic plaques (19). Advancements in stem cell technology have provided novel strategies for the treatment of heart disease (20). In the present study, the therapeutic effects of ESCs transplantation in a rat model of CAD were assessed. The results revealed that ESCs therapy decreased serum IL-1, IL-17 and TNFα levels and apoptosis in the myocardium of rats with CAD. ESCs therapy was demonstrated to regulate cardiac apoptosis via downregulating miRNA-146a expression in myocardial cells.

The current understanding of atherosclerosis pathophysiology emphasizes the role of inflammatory mediators in the development of CAD (21). IL-1 signaling may be regarded as an essential mediator in the pathogenesis of heart failure as it inhibits cardiac contractility, promotes myocardial hypertrophy and induces cardiomyocyte apoptosis (22). The results of the present study suggest that ESCs therapy decreases serum IL-1 levels in a CAD rat model. Bujak *et al* (22) reported that




Figure 3. ESCs therapy decreased myocardial infarction in a rat model of coronary heart disease. ESCs treatment (A) decreased the infarct area in the border zone (scale bar=2 mm). (B) increased VEGF expression (scale bar=50 mm) and (C) decreased sFas and TNFα expression compared with the control group (scale bar=50 mm). **P<0.01. ESCs, endothelial stem cells; VEGF, vascular endothelial growth factor; TNF, tumor necrosis factor.




Figure 4. ESCs therapy regulates cardiac apoptosis via downregulating miRNA-146a expression. (A) MiRNA-146a expression in myocardial cells isolated from rats treated with ESCs. (B) Transfection with miRNA-146aKN decreases VEGF, IL-6 and sICAM-1 protein expression in myocardial cells. (C) Transfection with pmiRNA-146a decreases the viability of myocardial cells compared with transfection with miRNA-mimics. (D) Transfection with miRNA-146aKN decreases sFas and TNFα expression in myocardial cells. *P<0.05 and **P<0.01. ESCs, endothelial stem cells; miRNA, microRNA; miRNA-146aKN, miRNA-146a knockdown; VEGF, vascular endothelial growth factor; IL, interleukin; ICAM-1, intercellular adhesion molecule 1; TNF, tumor necrosis factor. Control, miRNA-mimic for consistency.

serum IL-17 levels may be associated with predictive or prognostic values of ischemic heart disease. Li *et al* (23) revealed that serum TNF α levels transiently declined after 24 h of cardiopulmonary bypass and may be an important biological indicator for monitoring the efficacy of cardiopulmonary bypass in children with congenital heart disease. The results of the present study suggest that IL-17 and TNF α upregulation in CAD may be inhibited by ESCs therapy. However, further investigation is required to confirm the anti-inflammatory effects of ESCs in CAD.

It has previously been reported that ESCs are a valuable source of cell therapy for angiogenesis induction as a treatment for myocardial ischemia (23). The results of the present study indicate that the therapeutic effects of ESCs improve the atherosclerosis indices in a rat model of CAD compared with control rats. Wu *et al* (24) reported that miRNA-146a induced vascular smooth muscle cell apoptosis via the NF- κ B signaling pathway. In the present study, ESCs therapy decreased miRNA-146a expression and increased VEGF expression in the myocardium of rats with CAD. The results indicated that miRNA-146 inhibition reduced cardiac apoptosis and increased VEGF expression. Furthermore, it was demonstrated that ESCs therapy decreased serum AST, LDH, TnT and TnI levels in a rat model of CAD, as well as improving heart rate.

In conclusion, the results of the present study demonstrate the therapeutic effects of ESCs in decreasing inflammatory cytokines and the number of apoptotic cells in heart tissue. It was also demonstrated that miR-146a downregulation mediated by ESCs ameliorates the apoptosis of cardiac cells, suggesting that ESCs may have potential applications in CAD treatment.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The analyzed data sets generated during the present study are available from the corresponding author on reasonable request.

Authors' contributions

YF performed the experiments. SC, ZL, WA, XH, LW, PX and BJ prepared and analyzed experimental data. HF designed the experiments.

Ethics approval and consent to participate

This experiment was approved by the Ethics Committee of Shenzhen Nanshan People's Hospital.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Fan FF, Xu Q, Sun Q, Zhao SJ, Wang P and Guo XR: Assessment of the reporting quality of randomized controlled trials on treatment of coronary heart disease with traditional Chinese medicine from the Chinese journal of integrated traditional and Western medicine: a systematic review. *PLoS One* 9: e86360, 2014.
2. Doyle F, Rohde D, Rutkowska A, Morgan K, Cousins G and McGee H: Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with coronary heart disease: 1990 to 2013. *Psychosom Med* 76: 44-57, 2014.
3. Tully PJ and Baumeister H: Collaborative care for the treatment of comorbid depression and coronary heart disease: A systematic review and meta-analysis protocol. *Syst Rev* 3: 127, 2014.
4. Li SM, Xu H and Chen KJ: Integrative medicine on coronary heart disease: Annual academic review 2013. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 34: 1029-1034, 2014 (In Chinese).
5. Ray IB, Menezes AR, Malur P, Hiltbold AE, Reilly JP and Lavie CJ: Meditation and coronary heart disease: A review of the current clinical evidence. *Ochsner J* 14: 696-703, 2014.
6. Niermann C, Gorresen S, Klier M, Gowert NS, Billuart P, Kelm M, Merx MW and Elvers M: Oligophrenin1 protects mice against myocardial ischemia and reperfusion injury by modulating inflammation and myocardial apoptosis. *Cell Signal* 28: 967-978, 2016.
7. Guo CX, Jiang X, Zeng XJ, Wang HX, Li HH, Du FH and Chen BX: Soluble receptor for advanced glycation end-products protects against ischemia/reperfusion-induced myocardial apoptosis via regulating the ubiquitin proteasome system. *Free Radic Biol Med* 94: 17-26, 2016.
8. Shi ZY, Liu Y, Dong L, Zhang B, Zhao M, Liu WX, Zhang X and Yin XH: Cortistatin improves cardiac function after acute myocardial infarction in rats by suppressing myocardial apoptosis and endoplasmic reticulum stress. *J Cardiovasc Pharmacol Ther* 18: 2016.
9. Nishikido T, Oyama J, Shiraki A, Komoda H and Node K: Deletion of apoptosis inhibitor of macrophage (AIM)/CD5L attenuates the inflammatory response and infarct size in acute myocardial infarction. *J Am Heart Assoc* 5: e002863, 2016.
10. Volkman R and Offen D: Concise review: Mesenchymal stem cells in neurodegenerative diseases. *Stem Cells* 35: 1867-1880, 2017.
11. Ma T, Sun J, Zhao Z, Lei W, Chen Y, Wang X, Yang J and Shen Z: A brief review: Adipose-derived stem cells and their therapeutic potential in cardiovascular diseases. *Stem Cell Res* 8: 124, 2017.
12. Kane C and Terracciano CMN: Concise review: Criteria for chamber-specific categorization of human cardiac myocytes derived from pluripotent stem cells. *Stem Cells* 35: 1881-1897, 2017.
13. Lu X, Xia R, Zhang B and Gao F: MRI tracking stem cells transplantation for coronary heart disease. *Pak J Med Sci* 30: 899-903, 2014.
14. Hu YH, Wu HQ and Qi X: Influence of shenfu injection on heart function and bone marrow stem cell mobilization in patients with chronic heart failure of coronary heart disease. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 29: 309-312, 2009 (In Chinese).
15. Ghem C, Dias LD, Sant'Anna RT, Kalil RAK, Markoski M and Nardi NB: Combined analysis of endothelial, hematopoietic, and mesenchymal stem cell compartments shows simultaneous but independent effects of age and heart disease. *Stem Cells Int* 2017: 5237634, 2017.
16. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
17. Dirani M, Nasreddine W, Abdulla F and Beydoun A: Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel. *Epilepsy Behav Case Rep* 2: 164-166, 2014.
18. Li D, Wei W, Ran X, Yu J, Li H, Zhao L, Zeng H, Cao Y, Zeng Z and Wan Z: Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis. *Clin Chim Acta* 471: 38-45, 2017.

19. Feng B, Chen S, Gordon AD and Chakrabarti S: miR-146a mediates inflammatory changes and fibrosis in the heart in diabetes. *J Mol Cell Cardiol* 105: 70-76, 2017.
20. Tzatzalos E, Abilez OJ, Shukla P and Wu JC: Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies. *Adv Drug Deliv Rev* 96: 234-244, 2016.
21. Gidron Y, Kupper N, Kwaijtaal M, Winter J and Denollet J: Vagus-brain communication in atherosclerosis-related inflammation: A neuroimmunomodulation perspective of CAD. *Atherosclerosis* 195: e1-e9, 2007.
22. Bujak M and Frangogiannis NG: The role of IL-1 in the pathogenesis of heart disease. *Arch Immunol Ther Exp* 57: 165-176, 2009.
23. Li Z, Wu JC, Sheikh AY, Kraft D, Cao F, Xie X, Patel M, Gambhir SS, Robbins RC, Cooke JP and Wu JC: Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. *Circulation* 116: I46-54, 2007.
24. Wu ZW, Liu YF, Wang S and Li B: miRNA-146a induces vascular smooth muscle cell apoptosis in a rat model of coronary heart disease via NF-kappaB pathway. *Genet Mole Res* 14: 18703-18712, 2015.